Belfast-based ProAxsis, backed by VC group EMV Capital, has launched a fund raise of up to £800,000 to drive commercial expansion and clinical progress in chronic respiratory disease.
A spin-out from Queen’s University, ProAxsis is a respiratory diagnostics company specialising in biomarker-based tests for chronic lung diseases like COPD, cystic fibrosis, and bronchiectasis.
The company recently doubled revenues and is now gearing up for a major clinical study on its NEATstik® platform with Imperial College London.
EMV Capital plc (AIM: EMVC) is a London-based deeptech and life sciences VC investment group.